Impact of Immunosuppressive Therapy, Vaccination, and Monoclonal Antibody Use With Outcomes in Liver and Kidney Transplant Recipients With <scp>COVID</scp>‐19: A Retrospective Study
For organ transplant recipients with COVID-19, vaccination alone may not be an optimal strategy for preventing serious outcomes. Rather, the types of organ transplant, immunosuppressive therapy (particularly mycophenolate), and COVID-19 treatment strategy should be synergistically considered to promote an optimal therapeutic dynamic for a vulnerable population.
Authors
- Ali Jaan (ORCID: https://orcid.org/0000-0003-1155-7931)
- Zahid Ijaz Tarar (ORCID: https://orcid.org/0000-0001-7562-7420)
- Sara Farooqui
- Abdullah Sohail (ORCID: https://orcid.org/0000-0002-1240-6441)
- Adarsh Varma
- Ammad Chaudhary (ORCID: https://orcid.org/0000-0003-2986-3988)
- Ashley Francis
- Syed‐Mohammed Jafri (ORCID: https://orcid.org/0000-0001-8108-7408)
- Joseph P. Cavataio
Institutions
- Wayne State University (US)
- University of Iowa Hospitals and Clinics (US)
- Henry Ford Hospital (US)
- Rochester General Hospital (US)
- University of Missouri (US)
Publication Details
- Journal
- JGH Open
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/jgh3.70072
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00